FrancophonIA/ELRC3.0 huggingface dataset:
English: Tell your doctor if you have ever had an allergic reaction to any of the ingredients (including neomycin or any of the ingredients listed under section 6) before you receive this vaccine.
Danish: Informér lægen inden De får denne vaccine, hvis De på noget tidspunkt har haft en allergisk reaktion på indholdsstofferne i vaccinen (herunder neomycin eller et eller flere af indholdsstofferne, der er angivet under punkt 6).
English: The estimated vaccine efficacy during the LTPS follow-up period was 21% (95% CI: [11 to 30%]) for zoster incidence, 35% (95% CI: [9 to 56%]) for PHN incidence and 37% (95% CI: [27 to 46%]) for zoster BOI.
Danish: Den estimerede effekt af vaccinen i løbet af LTPS-opfølgningsperioden var 21 % (95 % CI: [11 til 30 %]) for zostertilfælde, 35 % (95 % CI: [9 til 56 %]) for PHN-tilfælde og 37 % (95 % CI: [27 til 46 %]) for zoster-BOI.
English: After reconstitution, use immediately or within 30 minutes if stored at 20°C-25°C.
Danish: Efter rekonstitution skal vaccinen anvendes straks eller inden for 30 minutter ved opbevaring ved 20 °C25 °C.
English: Furthermore, pregnancy should be avoided for 1 month following vaccination (see section 4.6).
Danish: Graviditet bør endvidere undgås i 1 måned efter vaccination (se pkt.
English: Monosodium L-glutamate monohydrate Disodium phosphate Sodium hydroxide (to adjust pH) Urea
Danish: Mononatrium-L-glutamatmonohydrat Dinatriumphosphat Natriumhydroxid (til justering af pH) Urea
English: 1, Oka/Merck strain, (live, attenuated) not less than 19,400 PFU (plaque-forming units).
Danish: 1, Oka/Merck-stamme, (levende, attenueret) ikke under 19.400 PFU (plaqueformende enheder).
English: Concurrent administration of ZOSTAVAX and anti-viral medications known to be effective against VZV has not been evaluated.
Danish: Samtidig indgivelse af ZOSTAVAX og antivirale lægemidler, der vides at yde beskyttelse mod VZV, er ikke blevet evalueret.
English: Lymphadenopathy (cervical, axillary)
Danish: Lympfadenopati (hals, aksil)
English: The estimated vaccine efficacy during the STPS follow-up period was 40% (95% CI: [18 to 56%]) for zoster incidence, 60% (95% CI: [-10 to 87%]) for PHN incidence and 50% (95% CI: [14 to 71%]) for zoster BOI.
Danish: Den estimerede effekt af vaccinen i løbet af STPS-opfølgningsperioden var 40 % (95 % CI: [18 til 56 %]) for zostertilfælde, 60 % (95 % CI: [-10 til 87 %]) for PHN-tilfælde og 50 % (95 % CI: [14 til 71 %]) for zoster-BOI.
English: Discard if reconstituted vaccine is not used within 30 minutes.
Danish: Rekonstitueret vaccine skal bortskaffes, hvis den ikke anvendes inden for 30 minutter.
English: The solvent is a clear, colourless fluid.
Danish: Solvensen er en klar, farveløs væske.
English: Ophthalmic zoster occurred in 35 subjects vaccinated with ZOSTAVAX vs. 69 subjects who received placebo.
Danish: Zoster ophthalmicus forekom hos 35 forsøgsdeltagere vaccineret med ZOSTAVAX versus 69 forsøgsdeltagere vaccineret med placebo.
English: The vaccine should be administered subcutaneously in patients with severe thrombocytopenia or any coagulation disorder (see section 4.4).
Danish: Vaccinen skal gives subkutant til patienter med svær trombocytopeni eller andre koagulationssygdomme (se pkt.
English: To reconstitute the vaccine, inject all the solvent in the pre-filled syringe into the vial of lyophilised vaccine and gently agitate to mix thoroughly.
Danish: For at rekonstituere vaccinen injiceres al solvens fra den forfyldte sprøjte i et hætteglas med frysetørret vaccine; omryst det forsigtigt, så det blandes helt.
English: Most of these adverse reactions were reported as mild in intensity.
Danish: De fleste af disse bivirkninger blev rapporteret som værende af mild sværhedsgrad.
English: ZOSTAVAX is indicated for immunization of individuals 50 years of age or older.
Danish: ZOSTAVAX er indiceret til vaccination af patienter i alderen 50 år eller derover.
English: Store and transport refrigerated (2C - 8C).
Danish: Opbevares i køleskab og transporteres nedkølet (2 C - 8 C).
English: After reconstitution, 1 dose (0.65 mL) contains: The active substance is:
Danish: Efter opløsning indeholder 1 dosis (0,65 ml): Aktivt stof:
English: In a double-blind, controlled clinical trial, 473 adults, 60 years of age or older, were randomised to receive a single dose of ZOSTAVAX either concomitantly (N=237), or nonconcomitantly (N=236) with 23-valent pneumococcal polysaccharide vaccine.
Danish: I et dobbeltblindet, kontrolleret klinisk studie blev 473 voksne på 60 år eller ældre randomiseret til at få en enkelt dosis ZOSTAVAX enten samtidig (N=237) eller ikke-samtidig (N=236) med en 23-valent pneumokokpolysaccharidvaccine.
English: In other clinical trials evaluating ZOSTAVAX in subjects 50 years of age or older, including a study of concomitantly administered inactivated influenza vaccine, a higher rate of injection-site adverse experiences of mild-to-moderate intensity was reported among subjects 50-59 years of age compared with subjects ≥60 years of age (see section 5.1).
Danish: I andre kliniske studier med undersøgelse af ZOSTAVAX til forsøgspersoner på 50 år eller derover (herunder et studie med samtidig administration af inaktiveret influenzavaccine) blev der rapporteret en større hyppighed af bivirkninger af mild til moderat sværhedsgrad på injektionsstedet hos forsøgspersoner i alderen 50-59 år end hos forsøgspersoner ≥60 år (se pkt.
English: • Rare (may affect up to 1 in 1,000 people): Hives at the injection site
Danish: • Sjældne (kan forekomme hos op til 1 ud af 1000 personer): nældefeber på injektionsstedet.
English: Inform your doctor if you are breast-feeding or intending to breast-feed.
Danish: Rådfør Dem med lægen, hvis De ammer eller planlægger at amme.
English: • Very common (may affect more than 1 in 10 people): Redness, pain, swelling and itching at the injection site*
Danish: • Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer): rødme, smerter, hævelse og kløe på injektionsstedet.
English: The VZV-specific immune responses to both vaccines at 4 weeks post-vaccination were similar, whether administered concomitantly or nonconcomitantly.
Danish: De VZV-specifikke immunresponser på begge vacciner 4 uger efter vaccinationen svarede til hinanden, uanset om de blev givet parallelt eller ikkeparallelt.
English: * Cox models adjusted for calendar time, age, sex, race/ethnic group, healthcare resource utilization (flu vaccination, number of weeks with an outpatient visit per year), co-morbid conditions (DxCG score, HCUP risk score), immunocompromise status during follow-up ‡ VE over study period is the VE calculated over the full duration of the study (2007-2014) at the time of this interim analysis § Average VE was calculated as the weighted average of the annual VE estimates over 3 and 5 years, respectively, where the weights are the proportion of the overall time period covered ¶ Data not available
Danish: * Cox-modeller justeret for kalendertid, alder, køn, race/etnisk gruppe, brug af helbredsressourcer (influenzavaccination, antal uger med et ambulant besøg pr. år), komorbiditeter (DxCG-score, HCUP-risikoscore), immunkompromitteret status i opfølgningsperioden ‡ VE i studieperioden er den VE, som blev beregnet under hele studiets varighed (2007-2014), på tidspunktet for denne interimanalyse § Gennemsnitlig VE blev beregnet som det vægtede gennemsnit af de årlige VE-estimater i løbet af henholdsvis 3 og 5 år, hvor vægtene er andelen af den samlede dækkede tidsperiode ¶ Data foreligger ikke
English: In an open-label study, ZOSTAVAX was administered as: (1) a booster dose to 201 zoster history-negative subjects 70 years of age or older who had received a first dose approximately 10 years previously as participants in the SPS, and (2) a first dose to 199 zoster history-negative subjects 70 years of age or older.
Danish: I et ikkeblindet studie blev ZOSTAVAX administreret som: (1) en boosterdosis til 201 forsøgspersoner i alderen 70 år og derover uden zoster i anamnesen, som havde fået den første dosis ca. 10 år tidligere som deltagere i SPS-studiet, og (2) den første dosis til 199 forsøgspersoner i alderen 70 år og derover uden zoster i anamnesen.
English: Hydrolysed gelatin
Danish: Hydrolyseret gelatin Natriumchlorid
English: At four weeks post-vaccination, the VZV-specific immune responses following concomitant use were not similar to the VZV-specific immune responses following nonconcomitant administration.
Danish: Fire uger efter vaccination svarede de VZV-specifikke immunresponser efter samtidig indgift ikke til de VZV-specifikke immunresponser ved ikke-samtidig indgift.
English: In a double-blind, controlled clinical trial, 762 adults 50 years of age and older were randomised to receive a single dose of ZOSTAVAX administered either concomitantly (N=382) or nonconcomitantly (N=380) with inactivated split influenza vaccine.
Danish: I et kontrolleret, dobbeltblindet klinisk studie, blev 762 voksne forsøgspersoner på 50 år eller ældre randomiseret til at modtage en enkelt dosis ZOSTAVAX enten parallelt (N=382) eller ikke-parallelt indgivet (N=380) med inaktiveret influenza-splitvaccine.
English: As for any vaccine, vaccination with ZOSTAVAX may not result in protection in all vaccine recipients.
Danish: Ligesom ved andre vacciner vil vaccination med ZOSTAVAX muligvis ikke beskytte alle vaccinerede.
English: The ZEST study was a placebo-controlled, double-blind clinical trial in which 22,439 subjects were randomised to receive a single dose of either ZOSTAVAX or placebo and were followed for the development of zoster for a median of 1.3 years (range 0 to 2 years).
Danish: ZEST-studiet var et placebokontrolleret, dobbeltblindet klinisk studie, hvor 22.439 forsøgspersoner blev randomiseret til at få en enkelt dosis af enten ZOSTAVAX eller placebo, og de blev kontrolleret for udvikling af zoster i mediant 1,3 år (spændvidde 0 til 2 år).
English: † VE was estimated for the first episode of herpes zoster during follow-up and was calculated as (1-hazards ratio)*100 * Cox models adjusted for calendar time, age, sex, race/ethnic group, healthcare resource utilization (flu vaccination, number of weeks with an outpatient visit per year), co-morbid conditions (DxCG score, HCUP risk score), immunocompromise status during follow-up ‡ VE over study period is the VE calculated over the full duration of the study (2007-2014) at the time of this interim analysis § Average VE was calculated as the weighted average of the annual VE estimates over 3 and 5 years, respectively, where the weights are the proportion of the overall time period covered ¶ Data not available
Danish: † VE blev estimeret for den første episode med herpes zoster i opfølgningsperioden og blev beregnet som (1-hazards ratio)*100 * Cox-modeller justeret for kalendertid, alder, køn, race/etnisk gruppe, brug af helbredsressourcer (influenzavaccination, antal uger med et ambulant besøg pr. år), komorbiditeter (DxCG-score, HCUP-risikoscore), immunkompromitteret status i opfølgningsperioden ‡ VE i studieperioden er den VE, som blev beregnet under hele studiets varighed (2007-2014), på tidspunktet for denne interimanalyse § Gennemsnitlig VE blev beregnet som det vægtede gennemsnit af de årlige VE-estimater i løbet af henholdsvis 3 og 5 år, hvor vægtene er andelen af den samlede dækkede tidsperiode ¶ Data foreligger ikke
English: Number of zoster cases
Danish: Antal zostertilfælde
English: Number of zoster confirmed cases
Danish: Antal verificerede zostertilfælde
English: Shingles is a painful, blistering rash.
Danish: Helvedesild er et smertefuldt, blæredannende udslæt.
English: Additional adverse reactions, spontaneously reported through post-marketing surveillance, are also included in Table 1.
Danish: Tabel 1 omfatter desuden bivirkninger, som er rapporteret spontant via overvågning efter markedsføring.
English: • History of hypersensitivity to the active substance, to any of the excipients or trace residuals (e.g. neomycin) (see sections 4.4 and 6.1).
Danish: • Anamnese med overfølsomhed over for det aktive stof, et eller flere af hjælpestofferne eller reststoffer (f.eks. neomycin) (se pkt.
English: , Swelling Injection site: Induration 1, Haematoma
Danish: Injektionsstedet: Induration 1, hæmatom varmefornemmelse
English: Vaccine-related injection-site adverse reactions were significantly greater for subjects vaccinated with ZOSTAVAX versus subjects who received placebo.
Danish: Forekomsten af vaccine-relaterede bivirkninger på injektionsstedet var signifikant større hos forsøgspersoner vaccineret med ZOSTAVAX end hos forsøgspersoner vaccineret med placebo.
English: Subjects on chronic/maintenance systemic corticosteroids In a double-blind, placebo-controlled, randomised clinical trial, ZOSTAVAX was administered to 206 subjects 60 years of age or older who were receiving chronic/maintenance systemic corticosteroid therapy at a daily dose equivalent of 5 to 20 mg of prednisone for at least 2 weeks prior to enrollment, and 6 weeks or more following vaccination to assess the immunogenicity and safety profile of ZOSTAVAX.
Danish: Forsøgspersoner i kronisk/vedligeholdelsesbehandling med systemiske kortikosteroider I et dobbeltblindet, placebokontrolleret, randomiseret klinisk studie blev ZOSTAVAX givet til 206 forsøgspersoner i alderen 60 år eller ældre, som var i kronisk/vedligeholdelsesbehandling med systemisk kortikosteroid med en daglig dosis svarende til 5 til 20 mg prednison i mindst 2 uger før indrullering og i 6 uger eller længere efter vaccination, for at vurdere ZOSTAVAX´ immunogenicitet og sikkerhedsprofil.
English: If you have experienced any of the following, talk to your doctor or pharmacist before receiving ZOSTAVAX:
Danish: Rådfør Dem med lægen eller apoteket, inden De får ZOSTAVAX, hvis De har oplevet et af følgende:
English: ZOSTAVAX significantly reduced the zoster pain Burden of Illness (BOI) score (see Table 5).
Danish: ZOSTAVAX medførte en signifikant reduktion af score for sygdomsbyrden (Burden of Illness, BOI) ved zostersmerter (se Tabel 5).
English: Adults with a history of herpes zoster (HZ) prior to vaccination ZOSTAVAX was administered to subjects 50 years of age or older with a history of herpes zoster (HZ) prior to vaccination (see section 5.1).
Danish: Voksne med tidligere herpes zoster (HZ) før vaccination ZOSTAVAX er blevet givet til forsøgspersoner på 50 år eller derover med tidligere herpes zoster (HZ) før vaccination (se pkt.
English: The median follow-up was ~1.2 years (range is one day to 2.2 years) and ~3.9 years (range is one week to 4.75 years) in STPS and LTPS, respectively.
Danish: I STPS og LTPS var den mediane opfølgning henholdsvis ~1,2 år (spændvidde 1 dag til 2,2 år) og ~3,9 år (spændvidde 1 uge til 4,75 år).
English: ZOSTAVAX significantly decreased the incidence of Post-herpetic Neuralgia (PHN) compared with placebo (see Table 4).
Danish: ZOSTAVAX medførte en signifikant reduktion af incidensen af postherpetisk neuralgi (PHN) sammenlignet med placebo (se Tabel 4).
English: Although, ZOSTAVAX is indicated as a single dose regimen (see section 4.2), a two-dose regimen was used.
Danish: Selvom ZOSTAVAX er indiceret som et endosisregime (se pkt.
English: , Pain/tenderness
Danish: , smerter/ømhed kløe
English: If you have a blood clotting disorder or low levels of platelets, the vaccine should be given under the skin because bleeding may occur following administration into the muscle.
Danish: Hvis De har en sygdom, der vedrører blodets evne til at størkne, eller hvis De har for få blodplader i blodet, skal indsprøjtningen gives under huden, da det kan begynde at bløde, hvis den bliver givet i en muskel.
English: Do not receive ZOSTAVAX
Danish: De må ikke få ZOSTAVAX
English: After reconstitution, 1 dose (0.65 mL) contains:
Danish: Efter opløsning indeholder 1 dosis (0,65 ml):
English: The frequency of vaccine-related adverse experiences after the second dose of ZOSTAVAX was generally similar to that seen with the first dose.
Danish: Hyppigheden af vaccine-relaterede bivirkninger efter den anden dosis ZOSTAVAX svarede alt i alt til den observerede hyppighed efter den første dosis.
English: Adults on chronic/maintenance systemic corticosteroids In subjects 60 years of age or older who were receiving chronic/maintenance systemic corticosteroid therapy at a daily dose equivalent of 5 to 20 mg of prednisone for at least 2 weeks prior to enrollment, and 6 weeks or more following vaccination, the safety profile was generally comparable to that seen in the Adverse Event Monitoring Substudy of the SPS (see sections 4.3 and 5.1).
Danish: Voksne i kronisk/vedligeholdelsesbehandling med systemiske kortikosteroider Hos forsøgspersoner på 60 år eller derover, som fik kronisk/vedligeholdelsesbehandling med systemisk kortikosteroid i en daglig dosis svarende til 5 til 20 mg prednison i mindst 2 uger før indrullering og i 6 uger eller længere efter vaccination, svarede sikkerhedsprofilen alt i alt til den observerede sikkerhedsprofil i det sekundære studie af bivirkninger i SPS (se pkt.
English: Powder and solvent for suspension for injection.
Danish: Pulver og solvens til injektionsvæske, suspension.
English: Table 2: Efficacy of ZOSTAVAX on zoster incidence compared with placebo in the ZEST trial in subjects 50 to 59 years of age*
Danish: Tabel 2: Effekten af ZOSTAVAX på incidensen af zoster sammenlignet med placebo i ZEST-studiet med forsøgspersoner i alderen 50 til 59 år*
English: * The analysis was performed on the Modified Intent-To-Treat (MITT) population that included all subjects randomised in the study who were followed for at least 30 days post-vaccination and did not develop an evaluable case of zoster within the first 30 days post vaccination † Age strata at randomisation were 60-69 and ≥ 70 years of age
Danish: * Analysen blev udført på den modificerede intent-to-treat (ITT) population, der omfattede alle randomiserede forsøgspersoner i studiet, som blev kontrolleret i mindst 30 dage efter vaccination, og som ikke fik et evaluerbart zoster-tilfælde inden for de første 30 dage efter vaccination.
English: Discard reconstituted vaccine if it is not used within 30 minutes.
Danish: Vaccinen skal bortskaffes, hvis den ikke anvendes inden for 30 minutter.
English: In another study, ZOSTAVAX was administered as a booster dose to HZ history-negative subjects 70 years of age or older who had received a first dose approximately 10 years previously, and as a first dose to HZ history-negative subjects 70 years of age or older (see section 5.1).
Danish: I et andet studie blev ZOSTAVAX givet som en boosterdosis til forsøgspersoner på 70 år eller derover uden HZ i anamnesen, som havde fået den første dosis ca. 10 år tidligere, og som den første dosis til forsøgspersoner på 70 år eller derover uden HZ i anamnesen (se pkt.
English: Gently agitate to dissolve completely.
Danish: Omryst forsigtigt for at opløse pulveret fuldstændigt.
English: The frequency of vaccine-related adverse experiences after the booster dose of ZOSTAVAX was generally similar to that seen with the first dose.
Danish: Hyppigheden af vaccine relaterede bivirkninger efter boosterdosis af ZOSTAVAX svarede alt i alt til den observerede hyppighedefter den første dosis.
English: The safety profile was generally similar to that seen in the Adverse Event Monitoring Substudy of the SPS.
Danish: Sikkerhedsprofilen svarede alt i alt til den observerede sikkerhedsprofil i det sekundære studie af bivirkninger i SPS.
English: ZOSTAVAX is a vaccine used to prevent shingles (zoster) and zoster-related post-herpetic neuralgia (PHN), the long-lasting nerve pain that follows shingles.
Danish: ZOSTAVAX er en vaccine, der anvendes til at forebygge helvedesild (herpes zoster) og zosterrelateret postherpetisk neuralgi (PHN), dvs. de langvarige nervesmerter, der følger efter helvedesild.
English: The Oka/Merck strain of VZV was not detected from any specimens in SPS or ZEST.
Danish: I SPS eller ZEST blev Oka/Merck-stammen af VZV ikke påvist i nogen prøver.
English: Inject the entire content of the syringe into the vial containing the powder.
Danish: Injicér hele sprøjtens indhold i hætteglasset med pulveret.
English: Headache and pain in the extremity were the most common systemic adverse reactions.
Danish: De mest almindelige systemiske bivirkninger var hovedpine og smerter i ekstremiteterne.
English: Vaccine-related serious adverse reactions were reported for 0.01% subjects vaccinated with ZOSTAVAX and subjects who received placebo.
Danish: Vaccine-relaterede alvorlige bivirkninger blev rapporteret hos 0,01 % af det samlede antal forsøgspersoner (dvs. forsøgspersoner vaccineret med ZOSTAVAX plus forsøgspersoner vaccineret med placebo).
English: • Uncommon (may affect up to 1 in 100 people): Nausea; swollen gland (neck, armpit)
Danish: • Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer): kvalme, hævede lymfeknuder (halsen, armhulen).
English: Sucrose, hydrolysed gelatin, urea, sodium chloride, potassium dihydrogen phosphate, potassium chloride, monosodium L-glutamate monohydrate, disodium phosphate, sodium hydroxide.
Danish: Saccharose, hydrolyseret gelatin, urea, natriumchlorid, kaliumdihydrogenphosphat, kaliumchlorid, mononatrium- L-glutamatmonohydrat, dinatriumphosphat, natriumhydroxid.
English: ZOSTAVAX cannot be used to treat existing shingles or the pain associated with existing shingles.
Danish: ZOSTAVAX kan ikke anvendes til behandling af helvedesild i udbrud eller smerter forbundet med helvedesild i udbrud.
English: Impaired vision occurred in 2 subjects vaccinated with ZOSTAVAX vs. 9 who received placebo.
Danish: Der forekom nedsat syn hos 2 forsøgsdeltagere vaccineret med ZOSTAVAX versus 9 forsøgsdeltagere vaccineret med placebo.
English: Withdraw the entire volume of solvent into a syringe.
Danish: Træk hele indholdet i hætteglasset med solvens op i en sprøjte.
English: One or 2 separate needles may be available in the secondary packaging of the presentation containing the pre-filled syringe without attached needle.
Danish: En eller to separate kanyler kan eventuelt findes i den mindre pakning i forsendelsen, der indeholder den forfyldte injektionssprøjte uden påmonteret kanyle.
English: Warmth 1, Rash, Pyrexia
Danish: 1, udslæt pyreksi
English: The powder is a white to off-white compact crystalline plug.
Danish: Pulveret er en hvid/råhvid kompakt krystallinsk "prop".
English: The most common adverse reactions reported in pivotal clinical trials were injection-site reactions.
Danish: I de pivotale kliniske studier var de hyppigst rapporterede bivirkninger reaktioner på injektionsstedet.
English: When completely reconstituted, the vaccine is a semi-hazy to translucent, off-white to pale yellow liquid.
Danish: Når vaccinen er fuldstændig rekonstitueret, er den en let sløret til gennemskinnelig, råhvid til bleggul væske.
English: HIV-infected adults with conserved immune function In a double-blind, placebo-controlled randomised clinical trial, ZOSTAVAX was administered to HIV-infected adults (18 years of age or older; median age 49 years) on appropriate antiretroviral therapy with conserved immune function (CD4+ T cell count ≥ 200 cells/µL).
Danish: I et dobbeltblindet, placebokontrolleret, randomiseret klinisk studie blev ZOSTAVAX givet til HIVinficerede voksne (18 år eller ældre, medianalder på 49 år) med bevaret immunfunktion (CD4+ T-celletal≥ 200 celler/µl), der fik passende antiretroviral behandling.
English: Table 4: Efficacy of ZOSTAVAX on PHN † incidence compared with placebo in the SPS in subjects 60 years of age and older*
Danish: Tabel 4: Effekten af ZOSTAVAX på incidensen af PHN † sammenlignet med placebo i SPS hos forsøgspersoner på 60 år og derover*
English: Rare (≥1/10,000 to <1/1,000);
Danish: Ikke almindelig (≥1/1.000 til <1/100); Sjælden (≥1/10.000 til <1/1.000);
English: VZV was detected in one (0.01%) specimen from a ZOSTAVAX recipient reporting a varicella/varicella-like rash; however, the virus strain (wild type or Oka/Merck strain) could not be determined.
Danish: VZV blev påvist i én (0,01 %) prøve fra en ZOSTAVAX-behandlet forsøgsperson, der rapporterede et varicella/varicellalignende udslæt.